Mitochondrial function in heart failure

Heart Failure Reviews

Volumn 4, Issue 3, 1999, Pages 229-244

  Schulze, Karsten ^a,b   Dörner, Andrea ^a   Schultheiß, Heinz Peter ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b Campus Benjamin Franklin   (Germany)

Author keywords

Adenine nucleotide; Ageing; Apoptosis; Energy metabolism; Heart failure; Mitochondria; Translocator

Indexed keywords

ADENINE NUCLEOTIDE; ADENINE NUCLEOTIDE TRANSLOCASE; ADENOSINE TRIPHOSPHATE; CREATINE KINASE; CYTOCHROME C; HEAT SHOCK PROTEIN; MITOCHONDRIAL DNA; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ENERGY METABOLISM; GENE MUTATION; HEART DILATATION; HEART FAILURE; HEART HYPERTROPHY; HEART MITOCHONDRION; HEART MUSCLE METABOLISM; HUMAN; HUMORAL IMMUNITY; ISCHEMIC HEART DISEASE; MITOCHONDRIAL ENERGY TRANSFER; MITOCHONDRIAL RESPIRATION; MYOCARDIAL HIBERNATION; OXIDATIVE STRESS; RECESSIVE INHERITANCE; REVIEW;

EID: 0033502071     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009810023405     Document Type: Review

References (219)

1. Von Korff RW. Metabolic characteristics of isolated rabbit heart mitochondria. J Biol Chem 1965;240:1351-1358.
2. Schwartz A, Lee KS. Study of heart mitochondria and glycolytic metabolism in experimentally induced cardiac failure. Circ Res 1962;10:321-332.
3. Plaut GWE, Gertler MM. Oxidative phosphorylation studies in normal and experimentally produced congestive heart failure in the guinea pig: A comparison. Ann NY Acad Sci 1959;72:515-517.
4. Szekeres L, Schein M. Cell metabolism of the overloaded mammalian heart in situ. Cardiologica 1959;34:18-27.
5. Wollenberger A, Kleitke B, Raabe G. Some metabolic characteristics of mitochondria from chronically overloaded hearts. Exp Molec Path 1963;2:251-260.
6. Argus MF, Arcos JC, Sardesai VM, Overby JL. Oxidative rates and phosphorylation in sarcosomes from experimentally-induced failing rat heart. Proc Soc Exp Biol Med 1964;117:380-383.
7. Olson RE. Abnormalities of myocardial metabolism. Circ Res 1964;15(Suppl II):109-119.
8. Sobel BE, Spann JF Jr, Pool PE, Sonnenblick EH, Braunwald E. Normal oxidative phosphorylation in mitochondria from failing heart. Circ Res 1967;21:355-363.
9. Schwartz A, Lindenmayer GE, Harigaya S. Respiratory control and calcium transport in heart mitochondria from the cardiomyopathic Syrian hamster. Trans NY Acad Sci 1968;30:951-954.
10. Kapelko VI, Veksler VI, Popovich MI, Ventura-Clapier R. Energy-linked functional alterations in experimental cardiomyopathies. Am J Physiol 1991;261(Suppl/Oct):39-44.
11. Sharov VG, Goussev A, Lesch M, Goldstein S, Sabbah HN. Abnormal mitochondrial function in myocardium of dogs with chronic heart failure. J Mol Cell Cardiol 1998;30: 1757-1762.
12. Unverferth DV, Magorien RD, Kolibash AJ, Lewis RP, Lykens M, Altschuld RA, Baba N, Leier CV. Biochemical and histologie correlates of ventricular end-diastolic pressure. Int J Cardiol 1981;1:133-142.
13. Bashore TM, Magorien DJ, Letterio J, Shaffer P, Unverferth DV. Histologic and biochemical correlates of left ventricular chamber dynamics in man. J Am Coll Cardiol 1987;9: 734-742.
14. 31P magnetic resonance spectroscopy using the reotating frame-depth selection technique. Ann NY Acad Sci 1987;508:321-332.
15. Schaefer S, Gober JR, Schwartz GG, Twieg DB, Weiner MW, Massie B. In vivo phosphorus-31 spectroscopic imaging in patients with global myocardial disease. Am J Cardiol 1990;65:1154-1161.
16. Hardy CJ, Weiss RG, Bottomley PA, Gerstenblith G. Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy. Am Heart J 1991;122: 795-801.
17. 31P-MR spectroscopy in patients with coronary artery disease and dilative cardiomyopathy. Circulation 1991; 84,4:11-379.
18. Chidsey CA, Weinbach EC, Pool PE, Morrow AG. Biochemical studies of energy production in the failing human heart. J Clin Invest 1966;45:40-50.
19. Lindenmayer GE, Sordahl LA, Harigaya S, Allen JC, Besch HR, Schwartz A. Some biochemical studies on subcellular systems isolated from fresh recipient human cardiac tissue obtained during transplantation. Am J Cardiol 1971;27: 277-284.
20. Sordahl LA, Liddicoat JE Jr, Diethrich EB, Silver B, De Bakey ME, Schwartz A. Respiratory activity of mitochondria from isolated human and dog hearts maintained in a portable preservation chamber. J Mol Cell Cardiol 1970; 1:379-388.
21. Shoffner JM, Wallace DC. Oxidative phosphorylation disease: disorder of two genomes. In: Harris H, Hirschhorn K, eds. Advances in Human Genetics. New York: Plenum Press 1990;19:267-330.
22. Anderson S, Bankier AT, Barrell BG, de Bruijn MHL, Coulson AR, Drouin J, Eperon IC, Nierlich DP, Roe BA, Sanger F, Schreier PH, Smith AHJ, Staden R, Young IG. Sequence and organization of the human mitochondrial genome. Nature 1981;290:457-465.
23. Wallace DC. Mitochondrial genetics: A paradigm for aging and degenerative disease. Science 1992;256:628-632.
24. Marin-Garcia J, Goldenthal MJ. Cardiomyopathy and abnormal mitochondrial function. Cardiovasc Res 1994;28:456-463.
25. Baandrup U, Florio LA, Rehahn M, Richardson PJ, Olsen EGJ. Critical analysis of endomyocardial biopsies from patients suspected of having cardiomyopathy. II. Comparison of histology and clinical/hemodynamic information. Br Heart J 1981;45:487-493.
26. Schwarz F, Mall G, Zebe H, Blickle J, Derks H, Manley J, Kubler W Quantitative morphologic findings in the myocardium in idiopathic dilated cardiomyopathy. Am J Cardiol 1983;51:501-506.
27. Maurer I, Zierz S. Myocardial respiratory chain enzyme activities in idiopathic dilated cardiomyopathy, and comparison with those in atherosclerotic coronary artery disease and valvular aortic stenosis. Am J Cardiol 1993;72:428-433.
28. Rustin P, Lebidois J, Chretien D, Bourgeron T, Piechaud JF, Rotig A, Munnich A, Sidi D. Endomyocardial biopsies for early detection of mitochondrial disorders in hypertrophic cardiomyopathies. J Pediatr 1994;124:224-228.
29. Hart Z, Chang C, DiMauro S, Farooki Q, Ayyar R. Muscle carnitine deficiency and fatal cardiomyopathy. Neurology 1978;28:147-151.
30. Tripp ME, Katcher ML, Peters HA. Systemic carnitine deficiency presenting as a familial endocardial fibroelastosis. A treatable cardiomyopathy. N Engl J Med 305'81: 385-390.
31. Waber LJ, Valle D, Neill C, DiMauro S, Shug A. Carnitine deficiency presenting as familial cardiomyopathy: A treatable defect in carnitine transport. J Pediatr 1982;101: 700-705.
32. Matsuishi T, Hirata K, Terasawa K, Kato H, Yoshino M, Ohtaki E, Hirose F, Nonaka I, Sugiyama N, Ohta K. Successful carnitine treatment in two siblings having lipid storage myopathy with hypertrophic cardiomyopathy. Neuropediatrics 1985;16:6-12.
33. (LEU)(UUR). Lancet 1991;338: 143-147.
34. Tanaka M, Ino H, Ohno K, Hattori K, Sato W, Ozawa T, Tanaka T, Itoyama S. Mitochondrial mutation in fatal infantile cardiomyopathy. Lancet 1990;336:1452.
35. Ozawa T, Tanaka M, Sugiyama S, Hattori K, Ito T, Ohno K, Takahashi A, Sato W, Takada G, Mayumi B, Yamamoto K, Adachi K, Koga Y, Toshima H. Multiple mitochondrial DNA deletions exist in cardiomyocytes of patients with hypertrophic or dilated cardiomyopathy. Biochem Biophys Res Commun 1990;170:830-836.
36. Morgan-Hughes JA, Hayes DJ, Cooper M, Clark JB. Mitochondrial myopathies: Deficiencies localized to complex I and complex III of the mitochondrial respiratory chain. Biochem Soc Trans 1985;13:648-651.
37. Channer KS, Channer JL, Campbell MJ, Rees JR. Cardiomyopathy in Kearns-Sayre syndrome. Br Heart J 1988;59:486-490.
38. Hayakawa M, Hattori K, Sugiyama S, Ozawa T. Age-associated oxygen damage and mutations in mitochondrial DNA in human hearts. Biochem Biophys Res Commun 1992;189: 979-985.
39. Sciacco M, Bonilla E, Schoen EA, Di Mauro S, Moraes CT. Distribution of wild-type and common deletion forms of mtDNA in normal and respiration-deficient muscle fibers from patients with mitochondrial myopathy. Hum Mol Genet 1994;3:13-19.
40. Bandy B, Davison AJ. Mitochondrial mutations may increase oxidative stress: Implications for carcinogenesis and aging? Free Rad Biol Med 1990;8:523-539.
41. Kowaltowski AJ, Vercesi AE. Mitochondrial damage induced by conditions of oxidative stress. Free Radic Biol Med 1999;26:463-471.
42. McMurray J, McLay J, Chopra M, Bridges A, Belch JJ. Evidence for enhanced free radical activity in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1990;65:1261-1262.
43. McMurray J, Chopra M, Abdullah I, Smith WE, Dargie HJ. Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J 1993;14:1493-1498.
44. Keith M, Geranmayegan A, Sole MJ, Kurian R, Robinson A, Omran AS, Jeejeebhoy AM. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1998;31:1352-1356.
45. Lochner A, Niekerk IV, Kotze JCN. Mitochondrial Acyl-CoA, adenine nucleotide translocase activity and oxidative phosphorylation in myocardial ischemia. J Mol Cell Cardiol 1981;13:991-997.
46. Rouslin W. Mitochondrial complexes I, II, III, IV, and V in myocardial ischemia and autolysis. Am J Physiol 1983;244: H743-H748.
47. Arroyo CM, Kramer JH, Leiboff RH, Mergner GW, Dickens BF, Weglicki WB. Spin trapping of oxygen and carbon-centered free radicals in ischemic canine myocardium. Free Rad Biol Med 1987;3:313-316.
48. McCord JM. Free Radicals and myocardial ischemia: Overview and outlook. Free Rad Biol Med 1988;4:9-14.
49. Otani H, Tanaka H, Inoue T. In vitro study of contribution of oxidative metabolism of isolated rabbit heart mitochondria to myocardial reperfusion injury. Circ Res 1984;55:168-175.
50. Dhalla AK, Signal PK. Antioxidant changes in hypertrophied and failing guinea pig hearts. Am J Physiol 1994;266: H1280-H1285.
51. Hill MF, Signal PK. Antioxidant and oxidative stress during heart failure subsequent to myocardial infarcteion in rats. Am J Pathol 1996;148:291-300.
52. Corral-Debrinsky M, Stepien G, Shoffner JM, Lott MT, Kanter K, Wallace DC. Hypoxia is asociated with mitochondrial DNA damage and gene induction. JAMA 1991;266: 1812-1816.
53. Li Y, Huang TT, Carlson EJ, Melov S, Ursell PC, Olson JL, Noble LJ, Yoshimura MP, Berger C, Chan PH. Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat Genet 1995;11: 376-381.
54. Skulachev VP. Cytochrome c in the apoptotic and antioxidant cascades. FEBS Lett 1998;423:275-280.
55. Harman D. The aging process. Proc Natl Acad Sci USA 1981;78:7124.
56. Fraga CG, Shigenaga MK, Park JW, Degan P, Ames BN. Oxidative damage to DNA during aging: 8-hydroxy-2′-deoxyguanosine in rat organ DNA and urine. Proc Natl Acad Sci USA 1990;87:4533-4537.
57. Stadtman ER. Protein oxidation and aging. Science 1992;257:1220-1224.
58. Marnett LJ, Hurd HK, Hollstein MC, Levin DE, Esterbauer H, Ames BN. Naturally occurring carbonyl compounds are mutagens in Salmonella tester strain TA104. Mutat Res 1985;148:25-34.
59. Papa S, Skulachev VP. Reactive oxygen species, mitochondria, apoptosis and aging. Mol Cell Biochem 1997;174: 305-319.
60. Ji LL, Dillon D, Wu E. Myocardial aging: Antioxidant enzyme systems and related biochemical properties. Am J Physiol 1991;261:R386-R392.
61. Beyer RE, Burnett B-A, Cartwright KJ, Edington DW, Falzon MJ, Kreitman KR, Kuhn TW, Ramp BJ, Rhee SYS, Rosenwasser MJ, Stein M, An LC. Tissue coenzyme Q (ubiquinone) and protein concentrations over the life span of the laboratory rat. Mech Ageing Dev 1985;32:267-281.
62. Abu-Erreish GM, Neely JR, Whitmer JT, Whitman V. Fatty acid oxidation by isolated perfused working hearts of aged rats. Am J Physiol 1977;232:E258-E262.
63. Shigenaga MK, Hagen TM, Ames BN. Oxidative damage and mitochondrial decay in aging. Proc Natl Acad Sci USA 1994;91:10771-10778.
64. Lee JC, Karpeles LM, Downing SE. Age-related changes of cardiac performance in male rats. Am J Physiol 1972;222: 432-438.
65. Olivetti G, Melissari M, Capasso JM, Anversa P. Cardiomyopathy of the aging human heart. Myocyte loss and reactive cellular hypertrophy. Circ Res 1991;68: 1560-1568.
66. Hachamovitch R, Wicker P, Capasso J, Anversa P. Alterations of coronary blood flow and reserve with aging in Fischer 344 rats. Am J Physiol 1989;256:H66-H73.
67. Hudson EK, Tsuchiya N, Hansford RG. Age-associated changes in mitochondrial mRNA expression and translation in the Wistar rat heart. Mech Ageing Dev 1998;103:179-193.
68. Marin-Garcia J, Ananthakrishnan R, Goldenthal MJ. Mitochondrial gene expression in rat heart and liver during growth and development. Biochem Cell Biol 1997;75: 137-142.
69. Andreu AL, Arbos MA, Perez-Martos A, Lopez-Perez MJ, Asin J, Lopez N, Montoya J, Schwartz S. Reduced mitochondrial DNA transcription in senescent rat heart. Biochem Biophys Res Commun 1998;252:577-581.
70. Clayton DA, Doda JN, Friedberg EC. The absence of a pyrimidine repair mechanism in mammalian mitochondria. Proc Natl Acad Sci USA 1974;71:2777-2781.
71. Richter C, Park JW, Ames BN. Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc Natl Acad Sci USA 1988;85:6465-6467.
72. Linnane A, Baumer A, Maxwell R, Preston H, Zhang C, Marzuki S. Mitochondrial gene mutation: The ageing process and degenerative disease. Biochem Int 1990;22:1067-1076.
73. Cortopassi G, Shibata D, Soong N, Arnheim N. A pattern of accumulation of a somatic deletion of mitochondrial DNA is aging human tissue. Proc Natl Acad Sci USA 1992;89: 7340-7344.
74. Hattori K, Tanaka M, Sugiyama S, Obayashi T, Ito T, Satake T, Hanaki Y, Asai J, Nagano M, Ozawa T. Age-dependent increase in deleted mitochondrial DNA in the human heart: Possible contributory factor to presbycadia. Am Heart J 1991;121:1735-1742.
75. Yoneda M, Katsumata K, Hayakawa M, Tanaka M, Ozawa T. Oxygen stress induces an apoptotic death associated with fragmentation of mitochondrial genome. Biochem Biophys Res Commun 1995;209:723-729.
76. Lewin MB, Timiras PS. Lipid changes with aging in cardiac mitochondrial membranes. Mech Ageing Dev 1984;24: 343-351.
77. Clandinin MT, Innis SM. Does mitochondrial ATP synthesis decline as a function of change in the membrane environment with aging? Mech Ageing Dev 1983;22:205-208.
78. Pieri C. Food restriction slows down age-related changes in cell membrane parameters. Ann NY Acad Sci 1991;621: 353-362.
79. Laganiere S, Yu BP. Modulation of membrane phospholipid fatty acid composition by age and food restriction. Gerontology 1993;39:7-18.
80. Choe MC, Jackson C, Yu BP. Lipid peroxidation contributes to age-related membrane rigidity. Free Radical Biol Med 1995;18:977-984.
81. Choudahary AK, Nokubo M, Reddy RG, Yoola SN, Morrow JD, Blair IA, Marnett LJ. Detection of endogenous malondialdehyde-deoxyguanosine adducts in human liver. Science 1994;265:1580-1582.
82. Kristal B, Chen JJ, Yu BP. Sensitivity of mitochondrial transcription to different free radical species. Free Radical Biol Med 1994;16:323-329.
83. Lucas DT, Szweda LI. Cardiac reperfusion injury: Aging, lipid peroxidation, and mitochondrial dysfunction. Proc Natl Acad Sci USA 1998;95:510-514
84. Hoch FL. Cardiolopins and biomembrane function. Biochim Biophys Acta 1992;1113:71-133.
85. Robinson NC. Functional binding of cardiolipin to cytochrome c oxidase. J Bioenerg Biomembr 1993;25:153-163.
86. Paradies G, Ruggiero FM, Petrosillo G, Quagliariello E. Age-dependent decline in the cytochrome c oxidase activity in rat heart mitochondria: Role of cardiolipin. FEBS Letters 1997;406:136-138.
87. Paradies G, Ruggiero FM, Petrosillo G, Quagliariello E. Age dependent impairment of mitochondrial function in rat heart tissue. Effect of pharmacological agents. Ann NY Acad Sci 1996;768:252-263.
88. Paradies G, Ruggiero FM, Petrosillo G, Quagliariello E. Peroxidative damage to cardiac mitochondria: Cytochrome oxidase and cardiolipin alterations. FEBS Lett 1998;424: 155-158.
89. Wittels B, Spann JF. Defective lipid metabolism in the failing heart. J Clin Invest 1968;47:1787-1794.
90. Schönekess BO, Allard MF, Lopaschuk GD. Propionyl L-carnitine improvement of hypertrophied rat heart function is associated with an increase in cardiac efficiency. Eur J Pharmacol 1995;286:155-166.
91. Gadaleta MN, Petruzzella V, Renis M, Fracasso F, Cantatore P. Reduced transcription of mitochondrial DNA in the senescent rat. Tissue dependence and effect of L-carnitine. Eur J Biochem 1990;187:501-506.
92. Dörner A, Pauschinger M, Badorff A, Noutsias M, Giessen S, Schulze K, Bilger J, Rauch U, Schultheiss H-P. Tissue-specific transcription pattern of the adenine nucleotide translocase isoforms in humans. FEBS Lett 1997;414: 2258-2262.
93. Dörner A, Schulze K, Rauch U, Schultheiss H-P. Adenine nucleotide translocator in dilated cardiomyopathy: Pathophysiological alterations in expression and function. Mol Cell Biochem 1997;174:261-269.
94. Schultheiss H-P. Dysfunction of the ADP/ATP carrier as a causative factor for the disturbance of the myocardial energy metabolism in dilated cardiomyopathy. Basic Res Cardiol 1992;87:311-320.
95. Sylven C, Lin L, Jansson E, Sotonyi P, Fu LX, Waagstein F, Hjalmarsson A, Marcus C, Bronnegard M. Ventricular adanine nucleotide translocator mRNA is upregulated in dilated cardiomyopathy. Cardiovasc Res 1993;27:1295-1297.
96. Gawaz M, Douglas MG, Klingenberg M. Structure-function studies of adenine nucleotide transport in mitochondria. II. Biochemical analysis of distinct AAC1 and AAC2 in yeast. J Biol Chem 1990;265:14202-14208.
97. Dörner A, Olesch M, Giessen S, Pauschinger M, Schultheiss H-P. Adenine nucleotide translocase isoform transcription in various tissues in the rat. Biochim Biophys Acta 1999;1417: 16-24.
98. Kühl U, Noutsias M, Seeberg B, Schannawell M, Lars B, Schultheiss H-P, Strauer BE. Chronic inflammation in dilated cardiomyopathy. Heart Failure 1994;9:231-245.
99. Schultheiss HP, Schulze K, Dörner A. Significance of the adenine nucleotide translocator in the pathogenesis of viral heart disease. Mol Cell Biochem 1996;163/164:319-327.
100. Schulze K, Witzenbichler B, Christmann C, Schultheiss H-P. Disturbance of myocardial energy metabolism in experimental virus myocarditis by antibodies against the adenine nucleotide translocator. Cardiovasc Res 1999;44:91-100.
101. Graham BH, Waymire KG, Cottrell B, Trounce IA, Mac Gregor GR, Wallace DC. A mouse model for mitochondrial myopathy and cardiomyopathy resulting from a deficiency in the heart/muscle isoform of the adenine nucleotide translocator. Nat Genet 1997;16:226-234.
102. Wessely R, Henke A, Zell R, Kandolf R, Knowlton KU. Low-level expression of a mutant coxsackieviral cDNA induces a myopathie effect in culture: An approach to the study of enteroviral persistence in cardiac myocytes. Circulation 1998;98:450-457.
103. Schulze K, Becker BF, Schultheiss HP. Antibodies to the ADP/ATP carrier, an autoantigen in myocarditis and dilated cardiomyopathy, penetrate into myocardial cells and disturb energy metabolism in vivo. Circ Res 1989;64: 179-192.
104. Schultheiss HP, Schulze K, Schauer R, Witzenbichler B, Strauer BE. Antibody-mediated imbalance of myocardial energy metabolism - a causal factor of cardiac failure? Circ Res 1995;76:64-72.
105. Khuchua ZA, Ventura-Clapier R, Kuznetsov AV, Grishin MN, Saks VA. Alterations in the creatine kinase system in the myocardium of cardiomyopathic hamsters. Biochem Biophys Res Commun 1989;165:748-757.
106. Liao R, Nascimben L, Friedrich J, Gwathmey JK, Ingwall JS. Decreased energy reserve in an animal model of dilated cardiomyopathy. Circ Res 1996;78:893-902.
107. Popovich M, Kostin S, Branishte T, Kobets V, Kapelko V. Cellular hypertrophy in cardiomyopathic patients is associated with lower creatine-stimulated mitochondrial respiration. Mol Cell Biochem 1995;143:1-5.
108. Nascimben L, Ingwall JS, Pauletto P, Friedrich J, Gwathmey JK, Saks VA, Pessina AC, Allen PD. Creatine kinase system in failing and nonfailing human myokardium. Circulation 1996;94:1894-1901.
109. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: A basic biologic phenomenon with wide ranging implications in tissue kinetics. Br J Cancer 1972;26:239-257.
110. Hetts SW. To die or not to die. An overview of apoptosis and its role in disease. JAMA 1998;279:300-307.
111. Haanen C, Vermes I. Apoptosis, programmed cell death in fetal development. Eur J Obstet Gynecol Reprod Biol 1996;64:129-133.
112. Majno G, Joris I. Apoptosis, oncosis, and necrosis: An overview of cell death. Am J Pathol 1995;146:3-15.
113. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-1462.
114. Kroemer G, Petit PX, Zamzami N, Vayssière J-L, Mignotte B. The biochemistry of apoptosis. FASEB J 1995;9:1277-1287.
115. Steller H. Mechanisms and genes of cellular suicide. Science 1995;267:1445-1449.
116. Williams GT, Smith CA. Molecular regulation of apoptosis: Genetic controls on cell death. Cell 1993;74:777-779.
117. Vaux DL, Haecker G, Strasser A. An evolutionary perspective on apoptosis. Cell 1994;76:777-779.
118. Yuan JY, Horvitz RH. Genetic mosaic analysis of ced-3 and ced-4, two genes that control programmed cell death in the nematode C. elegans. Dev Biol 1990;138:33-41.
119. Chinnaian AM, O'Rourke K, Lane BR, Dixit VM. Interaction of CED-4 with CED-3 and CED-9: A molecular frame work for cell death. Science 1997;275:1122-1126.
120. Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, Nitahara JA, Quaini E, Di Loreto C, Beltrami CA, Krajewski S, Reed JC, An versa P. Apoptosis in the failing human heart. N Engl J Med 1997;336:1131-1141.
121. Narula J, Haider N, Virmani R, Di Salvo TG, Kolodgie FD, Hajjar RJ, Schmidt U, Semigran MJ, Dec GW, Khaw BA. Apoptosis in myocytes in end-stage heart failure. N Engl J Med 1996;335:1182-1189.
122. Narula J, Hajjar RJ, Dec GW Apoptosis in the failing heart. Cardiol Clin 1998;16:691-710.
123. Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol 1997;80:15L-25L.
124. Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 1994;94:1621-1628.
125. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 1997;90:405-413.
126. Yang Y, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP, Wang X. Prevention of apoptosis by bcl-2: Release of cytochrome c from mitochondria blocked. Science 1997;275:1129-1132.
127. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: A primary site for bcl-2 regulation of apoptosis. Science 275+32-1136.
128. Vaux DL. CED-4-the third horseman of apoptosis. Cell 1997;90:389-390.
129. Reed JC. Double identity for proteins of the bcl-2 family. Nature 1997;387:773-776.
130. Gajewski TF, Thompson CB. Apoptosis meets signal transduction: Elimination of a BAD influence. Cell 1996;87:589-592.
131. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Brenner C, Larochette N, Prevost MC, Alzari PM, Kroemer G. Mitochondrial release of caspase-2 and -9 during the apoptotic process. J Exp Med 1999;189:381-394.
132. Zamzami N, Marchetti P, Castedo M, Zanin C, Vayssiere J-L, Petit PX, Kroemer G. Reduction in mitochndrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J Exp Med 1995;181: 1661-1672.
133. Golstein P. Controlling of cell death. Science 1997;275: 1081-1082.
134. Kroemer G, Zamzami N, Susin SA. Mitochondrial control of apoptosis. Immunol Today 1997;18:44-51.
135. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng T, Jones DP, Wang X. Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked. Science 1997;275:1129-1132.
136. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: A primary site fore Bcl-2 regulation of apoptosis. Science 1997;275: 1132-1136.
137. Tsuyimoto Y. Role of Bcl-2 family proteins in apoptosis: Apoptosomes or mitochondria? Genes Cells 1998;3:697-707.
138. Hunter DR, Haworth RA, Southard JH. Relationship between configuration, function, and permeability in calcium-treated mitochondria. J Biol Chem 1976;251:5069-5077.
139. 2+-induced membrane transition in mitochondria. I. The protective mechanisms. Arch Biochem Biophys 1979;195:453-459.
140. 2+ trigger site. Arch Biochem Biophys 1979;195:460-467.
141. 2+ release. Arch Biochem Biophys 1979;195:468-477.
142. 2+-activated hydrophilic channel of the mitochondrial inner membrane by nucleotides. J Membr Biol 1980;54:231-236.
143. Crompton M, Costi A. A heart mitochondrial pore of possible relevance to reperfusion-induced injury. Biochem J 1990; 266:33-39.
144. 2+-induced large-amplitude swelling of liver and heart mitochondria by cyclosporin in probably caused by the inhibitor binding to mitochondrial-matrix peptidyl-prolyl cis-trans isomerase and preventing it interacting with the adenine nucleotide translocase. Biochem J 1990;268:153-160.
145. 2+. Biochemistry 1996;35:8483-8488.
146. Fontaine E, Eriksson O, Ichas F, Bernardi P. Regulation of the permeability transition pore in skeletal muscle mitochondria. Modulation by electron flow through the respiratory chain complex I. J Biol Chem 1998;273-662-12668.
147. Beutner G, Rück A, Riede B, Weite W, Brdiczka D. Complexes between kinases, mitochondrial porin, and adenylate translocator in rat brain resemble the permeability transition pore. FEBS Lett 1996;396:189-195.
148. O'Gorman E, Beutner G, Dolder M, Koretsky AP, Brdiczka D, Wallimann T. The role of creatine kinase in inhibition of mitochondrial permeability transition. FEBS Lett 1997;414: 253-257.
149. 2+-dependent pore in heart mitochondria activated by inorganic phosphate and oxidative stress. Biochem J 1988;255:357-360.
150. Bernardi P. Modulation of the mitochondrial cyclosporin A-sensitive permeability transition pore by the proton electrochemical gradient. Evidence that the pore can be opened by membrane depolarization. J Biol Chem 1992;267:8834-8839.
151. Zoratti M, Szabo I. The mitochondrial permeability transition. Biochim Biophys Acta 1995;1241:139-176.
152. Halestrap AP, Woodfield KY, Connern CP. Oxidative stress, thiol reagents, and membrane potential modulate the mitochondrial permeability transition by affecting nucleotide binding to the adenine nucleotide translocase. J Biol Chem 1997;272:3346-3354.
153. Halestrap AP. Calcium-dependent opening of a non-specific pore in the mitochondrial inner membrane is inhibited at pH values below 7 - Implications for the protective effect of low pH against chemical and hypoxic cell damage. Biochem J 1991;278:715-719.
154. Nieminen A-L, Byrne AM, Herman B, Lemasters JJ. Mitochondrial permeability transition in hepatocytes induced by t-BuOOH: NAD(P)H and reactive oxygen species. Am J Physiol 1997;272:C1286-C1294.
155. Bradham CA, Qian T, Brenner DA, Lemasters JJ. Tumor necrosis factor α (TNFα)-mediated apoptosis in Iκ-AA-sensitized hepatocytes requires the mitochondrial permeability transition. Mol Biol Cell 1997;8:32a.
156. Griffiths EJ, Halestrap AP. Protection by cyclosporin A of ischemia-reperfusion induced damage in isolated rat hearts. J Mol Cell Cardiol 1993;25:1461-1469.
157. Nazareth W, Yafei N, Crompton M. Inhibition of anoxia-induced injury in heart myocytes by cyclosporin-A. J Mol Cell Cardiol 1991;23:1351-1354.
158. Fournier N, Ducet G, Crevat A. Action of cyclosporin on mitochondrial calcium fluxes. J Bioenerg Biomembr 1987; 19:297-303.
159. Broekemeier KM, Dempsey ME, Pfeiffer DR. Cyclosporin A is a potent inhibitor of the inner membrane permeability transition in liver mitochondria. J Biol Chem 1989;264:7826-7830.
160. Nicolli A, Basso E, Petronelli V, Wenger RM, Bernardi P. Interactions of cyclophilin with the mitochondrial inner membrane and regulation of the permeability transition pore, a cyclosporin A-sensitive channel. J Biol Chem 1996; 271:2185-2195.
161. Kerr PM, Suleiman MS, Halestrap AP. Reversal of permeability transition during recovery of hearts from ischemia and its enhancement by pyruvate. Am J Physiol 1999;276: H496-H502.
162. Ichas F, Mazat JP. From calcium signaling to cell death: Two conformations for the mitochondrial permeability transition pore. Switching from low- to high-conductance state. Biochim Biophys Acta 1998;1366:33-50.
163. Levine B, Kaiman J, Mayer L, Fillit HM, Packer M. Elevated circulationg levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236-241.
164. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 1994;72:561-566.
165. Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, Mann DL. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing heart. Circulation 1996;93:704-711.
166. Hegewisch S, Weh HJ, Hossfeld DK. TNF-alpha induced cardiomyopathy. Lancet 1990;335:294-295.
167. Kapadia SR, Oral H, Lee J, Nakano M, Taffet GE, Mann DL. Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium. Circ Res 1997;81:187-195.
168. Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, Demetris AJ, Feldman AM. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Cir Res 1997;81:627-635.
169. Bozkurt B, Kribbs SB, Clubb FJ, Michael DH, Didenko VV, Hornsby PJ, Seta Y, Oral H, Spinale FG, Mann DL. Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998;97:1382-1391.
170. Aukrust P, Ueland T, Lien E, Bendtzen K, Muller F, Andreassen AK, Nordøy I, Aass H, Espevik T, Simonsen S, Frøland SS, Gullestad L. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1999;83:376-382.
171. Kruit WH, Punt KJ, Goey SH, de Mulder PH, van Hoogenhuyze DC, Henzen-Logmans SC, Stoter G. Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. An unexpectedly frequent complication. Cancer 1994;74: 2850-2856.
172. Zell R, Geck P, Werdan K, Boekstegers P. TNF-α and IL-α inhibit both pyruvate dehydrogenase activity and mitochondrial function in cardiomyocytes: Evidence for primary impairment of mitochondrial function. Mol Cell Biochem 1997;177:61-67.
173. Schulze-Ostroff K, Bakker AC, Vanhaesebroeck B, Beyaert R, Jacob WA, Fiers W. Cytosolic activity of tumor necrosis factor is mediated by early damage of mitochondrial functions. Evidence for the involvement of mitochondrial radical generation. J Biol Chem 1992;267:5317-5323.
174. Jia L, Kelsey SM, Grahn MF, Jiang XR, Newland AC. Increased activity and sensitivity of mitochondrial respiratory enzymes to tumor necrosis factor alpha-mediated inhibition is assoxiated with increased cytotoxicity in drug-resistant leucemic cell lines. Blood 1996;87:2401-2410.
175. Hennet T, Richter C, Peterhans E. Tumour necrosis factor-alpha induces Superoxide anion generation in mitochondria of L929 cells. Biochem J 1993;289:587-592.
176. Goossens V, Grooten J, De Vos K, Fiers W. Direct evidence for tumor necrosis factor-induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity. Proc Natl Acad Sci USA 1995;92:8115-8119.
177. Kolesnick R, Golde DW. The sphingomyelin pathway in tumor necrosis factor and interleukin-1 signaling. Cell 1994; 77:325-328.
178. Hannun YA. Functions of ceramide in coordinating cellular responses to stress. Science 1996;274:55-1859.
179. Gudz TI, Tserng KY, Hoppel CL. Direct inhibition of mitochondrial respiratory chain complex III by cell-permeable ceramide. J Biol Chem 1997;272:24154-24158.
180. Amarante-Mendes GP, Naekyung KC, Liu L, Huang Y, Perkins CI, Green DR, Bhalla K. Ber-Abl exerts ist antiapoptotic effect against diverse apoptotic stimuli through blockade of mitochondrial release of cytochrome C and activation of caspase-3. Blood 1998;91:1700-1705.
181. Eddy LJ, Goeddel DV, Wong GH. Tumor necrosis factor-alpha pretreatment is protective in a rat model of myocardial ischemia-reperfusion injury. Biochem Biophys Res Commun 1992;184:1056-1059.
182. Nathan C, Xie QW. Nitric oxide synthases: Roles, tolls, and controls. Cell 1994;78:915-918.
183. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992;257:387-389.
184. Barry WH. Mechanisms of immune-mediated myocyte-injury. Circulation 1994;89:2421-2432.
185. Kinugawa K, Takahashi T, Kohmoto O, Yao A, Aoyagi T, Momomura S, Hirata Y, Serizawa T. Nitric oxide-mediated effects of interleukin-6 on [Ca2+]i and cell concentration in cultured chick ventricular myocytes. Circ Res 1994;75:285-292.
186. Shen W, Xu X, Ochoa M, Zhao G, Wolin MS, Hintze TH. Role of nitric oxide in the regulation of oxygen consumption in conscious dogs. Circ Res 1994;75:1086-1095.
187. Shah AM, Spurgeon HA, Sollot SJ, Talo A, Lakatta EG. 8-bromo-cGMP reduces the myofilament response to Ca2+ in intact cardiac myocytes. Circ Res 1994;74:970-978.
188. Oddis CV, Finkel MS. Cytokine-stimulated nitric oxide production inhibits mitochondrial activity in cardiac myocytes. Biochem Biophys Res Commun 1995;213:1002-1009.
189. Granger DL, Lehninger AL. Sites of inhibition of mitochondrial electron transport in macrophage-induced neoplastic cells. J Cell Biol 1982;95:527-535.
190. Drapier JC, Hibbs JB, Murine cytotoxic macrophages inhibit acotinase in tumor cells: Inhibition involves the iron-sulfur prosthetic group and is reversible. J Clin Invest 1986;78:790-797.
191. O'Murchu B, Miller VM, Perrella MA, Burnett JC. Increased production of nitric oxide in coronary arteries during congestive heart failure. J Clin Invest 1994;93:165-171.
192. Xie Y-W, Shen W, Zhao G, Xu X, Wolin MS, Hintze TH. Role of endothelium-derived nitric oxide in the modulation of canine myocardial mitochondrial respiration in vitro. Implications for the development of heart failure. Circ Res 1996;79:381-387.
193. Knowlton AA, Kapadia S, Torre-Amione G, Durand JB, Bies R, Young J, Mann DL. Differential expression of heat shock proteins in normal and failing heart. J Mol Cell Cardiol 1998;30:811-818.
194. Knowlton AA. Heat-shock proteins, stress, and the heart. Ann NY Acad Sci 1994;723:128-136.
195. Agsteribbe E, Huckriede A, Veenhuis M, Ruiters MHJ, Niezen-Koning KE, Skjeldal OH, Skullerud K, Gupta RS, Hallberg R, van Diggelen OP, Scholte HR. A fatal, systemic mitochondrial disease with decrease mitochondrial enzyme activities, abnormal ultrastructure of the mitochondria and deficiency of heat shock protein 60. Biochem Biophys Res Commun 1993;193:146-154.
196. Rauch U, Schulze K, Witzenbichler B, Schultheiss HP. Alteration of the cytosolic-mitochondrial distribution of high-energy phosphates during global myocardial ischemia may contribute to early contractile failure. Circ Res 1994;75:760-769.
197. Noll T, Koop A, Piper HM. Mitochondrial ATP-synthase activity in cardiomyocytes after aerobic-anaerobic metabolic transition. Am J Physiol 1992;262:C1297-C1303.
198. Piper HM, Sezer O, Schleyer M, Schwartz P, Hütter JF, Spieckermann PG. Development of ischemia-induced damage in defined mitochondrial subpopulations. J Mol Cell Cardiol 1985;17:186-198.
199. Rouslin W. Mitochondrial complexes I, II, III, IV, and V in myocardial ischemia and autolysis. Am J Physiol 1983;244:H743-H748.
200. Pauly DF, Yoon SB, McMillin JB. Carnitine-acylcarnitine translocase in ischemia: Evidence for sulfhydryl modification. Am J Physiol 1987;253:H1557-H1565.
201. Shug AL, Shrago E, Bittar N, Folts JD, Roke JR. Acyl CoA inhibition of adenine nucleotide translocation in ischemic myocardium. Am J Physiol 1975;228:689-692.
202. Bond JM, Chacon E, Herman B, Lemasters JJ. Intracellular pH and calcium homeostasis during the pH paradox of reperfusion injury to cultured neonatal rat cardiac myocytes. Am J Physiol 1993;263:C129-C137.
203. +, and the mitochondrial permeability transition inreperfusion injury to rat hepatocytes: Protection bycyclosporin A and glycine. Am J Physiol 1997;273:C1783-C1792.
204. Bolli R. Mechanism of myocardial "stunning". Circulation 1990;82:723-738.
205. Ellis SG, Henschke CI, Sandor T, Wynne J, Braunwald E, Kloner RA. Time course of functional and biochemical recovery of myocardium salvaged by reperfusion. J Am Coll Cardiol 1983;1:1047-1055.
206. Reimer KA, Hill ML, Jennings RB. Prolonged depletion of ATP and of the adenine nucleotide pool due to delayed resynthesis of adenine nucleotides following reversible myocardial ischemic injury in dogs. J Mol Cell Cardiol 1981:13:229-239.
207. Swain JL, Sabina RL, Mc Hale PA, Greenfield JC Jr, Holmes EW. Prolonged myocardial nucleotide depletion after brief ischemia in the open-chest dog. Am J Physiol 1982;242: H818-H826.
208. Neely JR, Grotyohann LW. Role of glycolytic products in damage to ischemic myocardium: Dissociation of adenosine triphosphate levels and recovery of function of reperfused ischemic hearts. Circ Res 1984;55:816-824.
209. Ambrosio G, Jacobus WE, Bergmann CA, Weisman HF, Becker LC. Preserved high energy phosphate metabolic reserve in globally "stunned" hearts despite reduction of basal ATP content and contractility. J Mol Cell Cardiol 1987;19:953-964.
210. Taegtmeyer H, Roberts AFC, Raine AEG. Energy metabolism in reperfused heart muscle: Metabolic correlates to return of function. J Am Coll Cardiol 1985;6:864-780.
211. Ambrosio G, Jacobus WE, Mitchell MC, Litt MR, Becker LC. Effects of ATP precursors on ATP and free ADP content and functional recovery of postischemic hearts. Am J Physiol 1989;256:H560-H566.
212. Hoffmeister HM, Mauser M, Schaper W. Effect of adenosine and AICA ribose on ATP content and regional contractile function in reperfused canine myocardium. Basic Res Cardiol 1985;80:445-458.
213. Becker LC, Levine JH, Di Paula AF, Guarnieri T, Aversano TR. Reversal of dysfunction in postischemic stunned myocardium by epinephrine and postextrasystolic potentiation. J Am Coll Cardiol 1986;7:580-589.
214. Mercier JC, Lando U, Kanmatuse K, Ninomiya K, Meerbaum S, Fishbein MC, Sean HJC, Ganz W Divergent effects of inotropic stimulation on the ischemic and severely depressed reperfused myocardium. Circulation 1982;66:397-400.
215. Arnold JMO, Braunwald E, Sandor T, Kloner RA. Inotropic stimulation of reperfused myocardium with dopamine: Effects on infarct size and myocardial function. Am Heart J 1984;107:9-13.
216. Ito BR, Tate H, Kobayashi M, Schaper W. Reversibly injured, postischemic canine myocardium retains normal contractile reserve. Circ Res 1987;61:834-846.
217. Ferrari R, Ceconi C, Curello S, Benigno M, La Canna G, Visioli O. Left ventricular dysfunction due to the new ischemic outcomes: Stunning and hibernation. J Cardiovasc Pharmacol 1996;28(Suppl 1):S18-S26.
218. Schulz R, Guth BD, Pieper K, Martin C, Keusch G. Recruitment of an inotropic reserve in moderately ischemic myocardium at the expense of metabolic recovery: A model of short-term hibernation. Circ Res 1992;70:1282-1295.
219. Ferrari R, Cargnoni A, Curello S, Ceconi C, Volpini M, Visioli O. Metabolic adaptation of underperfused isolated rabbit heart: An insight into molecular mechanisms underlying hibernation. Circulation 1993;88:1004 (Abstract).